Oregon Medical Research Center

Portland, Oregon 97223-6683

3 studies enrolling now · 67 studies all time

What they study most

Actinic Keratosis, Alopecia, Alopecia Areata, Atopic Dermatitis, Atopic Dermatitis Eczema, Cardiovascular Diseases, Central Abdominal Bulging, Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU), Cutaneous Lichen Planus, Dermatitis, Dermatitis, Atopic

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo — Recruiting now
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) — Stopped early
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis — Completed
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• Long-Term PF-06651600 for the Treatment of Alopecia Areata — Completed
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Running, not enrolling
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• High Dose Risankizumab for Psoriasis — Completed
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Running, not enrolling
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) — Completed
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema — Completed
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) — Completed
• Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis — Completed
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) — Completed
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus — Completed
• A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis — Completed
• A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis — Status unconfirmed
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 — Withdrawn before enrolling
• Vascular Inflammation in Psoriasis - Apremilast — Completed
• Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis — Completed
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects — Completed
• A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis — Completed
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• AGN-242428 in the Treatment of Plaque Psoriasis — Stopped early
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) — Completed
• Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea — Completed
• Study of A-101 for the Treatment of Seborrheic Keratosis — Completed
• A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail — Completed
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis — Completed